Freestone Grove Partners LP Humacyte, Inc. Transaction History
Freestone Grove Partners LP
- $8.16 Trillion
- Q4 2024
A detailed history of Freestone Grove Partners LP transactions in Humacyte, Inc. stock. As of the latest transaction made, Freestone Grove Partners LP holds 38,899 shares of HUMA stock, worth $145,871. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,899Holding current value
$145,871% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding HUMA
# of Institutions
172Shares Held
41MCall Options Held
553KPut Options Held
942K-
Black Rock Inc. New York, NY7.14MShares$26.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.6MShares$21 Million0.0% of portfolio
-
State Street Corp Boston, MA4.61MShares$17.3 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA2.85MShares$10.7 Million0.11% of portfolio
-
Geode Capital Management, LLC Boston, MA2.14MShares$8.01 Million0.0% of portfolio
About Humacyte, Inc.
- Ticker HUMA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,007,000
- Market Cap $386M
- Description
- Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...